LVLorena Vega-Piris

Lorena Vega-Piris

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lorena Vega-Piris has a total of 132 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Prognostic factors of early mortality in children and adolescents with relapsed/refractory solid tumors participating in dose-finding trials in the targeted and immune therapies era: An ITCC study

    by Fernando Carceller, Francisco Bautista, Harm Van Tinteren, Alicia Castañeda, Aurore Surun, Ajla Wasti, Gabriel Revon-Rivière, Luca Bergamaschi, Marta Cortés, Raquel Hladun-Álvaro, et al.


  • Open Access

    Effectiveness of XBB.1.5 Vaccines Against Symptomatic SARS‐CoV‐2 Infection in Older Adults During the JN.1 Lineage‐Predominant Period, European VEBIS Primary Care Multicentre Study, 20 November 2023–1 March 2024

    by Lore Merdrignac, Charlotte Laniece Delaunay, Nuno Verdasca, Lorena Vega‐Piris, Joan O'DOnnell, Noémie Sève, Camino Trobajo‐Sanmartín, Silke Buda, Mariëtte Hooiveld, Ana Paula Rodrigues, et al.

    We estimated XBB.1.5 vaccine effectiveness (VE) against symptomatic SARS‐CoV‐2 infection among adults aged ≥ 65 years during the 2023/2024 JN.1 lineage‐predominant period in a European multi‐country test‐negative case–control study at primary care level. We estimated VE adjusted by study site, age, sex, chronic conditions and onset date. We included 220 cases and 1733 controls. The VE was 48% (95% CI: 12–71), 23% (95% CI: −11–48) and 5% (95% CI: −92–56) among those with symptom onset 1–5, 6–11, and ≥ 12 weeks after vaccination, respectively. XBB.1.5 vaccine provided short and moderate protection against JN.1 symptomatic infection.


  • Open Access

    Severity of respiratory syncytial virus compared with SARS-CoV-2 and influenza among hospitalised adults ≥65 years

    by Lorena Vega-Piris, Silvia Galindo Carretero, José Luis Mayordomo, Mercedes Belén Rumayor Zarzuelo, Virginia Álvarez Río, Virtudes Gallardo García, Miriam García Vázquez, María del Carmen García Rodríguez, Luca Basile, Nieves López González-Coviella, et al.


  • Open Access

    Epidemiología y carga de enfermedad por VRS en España. SiVIRA, temporadas 2021-22 y 2022-23

    by Tania Carolina Puma Olguin, Clara Mazagatos, Silvia Galindo-Carretero, Lorena Vega-Piris, Marcos Lozano-Álvarez, Gloria Pérez-Gimeno, Susana Monge, Amparo Larrauri

    Introducción: Es esencial conocer la carga de enfermedad de la infección respiratoria aguda por Virus Respiratorio Sincitial (VRS) antes de la implementación de cualquier medida preventiva. El objetivo de este estudio es describir la epidemiología de la infección por VRS y estimar su carga de enfermedad en España a partir del Sistema de Vigilancia de Infección Respiratoria Aguda (SiVIRA). Método: Con datos de SiVIRA se estimaron casos en Atención Primaria y hospitalizaciones por VRS, por grupo de edad, en las temporadas de 2021-22 a 2022-23. Las hospitalizaciones estimadas con SiVIRA se compararon con datos de altas hospitalarias por VRS en el periodo 2016-2020, obtenidas del Conjunto Mínimo Básico de Datos (CMBD). Resultados: SiVIRA estimó un promedio por temporada de 907.194 casos en Atención Primaria y 29.081 hospitalizaciones por VRS en España. Los <5 años concentraron 259.013 casos (28,6%) y 15.375 hospitalizaciones (52,9%), y requirieron con mayor frecuencia ventilación mecánica invasiva (6,9%) y admisión en la Unidad de Cuidados Intensivos (UCI) (14,4%). En ≥65 años se estimaron 128.590 casos (14,2%) y 10.360 hospitalizaciones (35,6%). En el análisis ampliado del CMBD, se observaron 21.258 hospitalizaciones en <5años (42,4%), y 22.758 en los ≥65 años (45,4%). Conclusiones: El mayor impacto de la infección por VRS se produce en los niños <5 años, especialmente en <1 año. La considerable carga hospitalaria en adultos mayores aconseja valorar medidas preventivas de salud pública. Las estimaciones de carga hospitalaria a partir de la vigilancia SiVIRA fueron comparables a las obtenidas con el análisis ampliado del CMBD.


  • Open Access

    The Impact of COVID-19 on Mortality in Spain: Monitoring Excess Mortality (MoMo) and the Surveillance of Confirmed COVID-19 Deaths

    by Inmaculada León-Gómez, Clara Mazagatos, Concepción Delgado-Sanz, Luz Frías, Lorena Vega-Piris, Ayelén Rojas-Benedicto, Amparo Larrauri

    Measuring mortality has been a challenge during the COVID-19 pandemic. Here, we compared the results from the Spanish daily mortality surveillance system (MoMo) of excess mortality estimates, using a time series analysis, with those obtained for the confirmed COVID-19 deaths reported to the National Epidemiological Surveillance Network (RENAVE). The excess mortality estimated at the beginning of March 2020 was much greater than what has been observed in previous years, and clustered in a very short time. The cumulated excess mortality increased with age. In the first epidemic wave, the excess mortality estimated by MoMo was 1.5 times higher than the confirmed COVID-19 deaths reported to RENAVE, but both estimates were similar in the following pandemic waves. Estimated excess mortality and confirmed COVID-19 mortality rates were geographically distributed in a very heterogeneous way. The greatest increase in mortality that has taken place in Spain in recent years was detected early by MoMo, coinciding with the spread of the COVID-19 pandemic. MoMo is able to identify risk situations for public health in a timely manner, relying on mortality in general as an indirect indicator of various important public health problems.


  • Pharmacokinetic variability of eslicarbazepine in real clinical practice

    by Maria de Toledo, Laura Valladares-Salado, Jose Cebrian-Escudero, Carolina Diaz-Perez, Elisa de la Fuente, Raquel Ferreiros, Elena Sanz-Sanz, Lorena Vega-Piris, Alfonso Lagares, Maria C Ovejero-Benito, et al.


  • Open Access

    CCR7 as a novel therapeutic target in t-cell PROLYMPHOCYTIC leukemia

    by Carlos Cuesta-Mateos, Patricia Fuentes, Alexandra Schrader, Raquel Juárez-Sánchez, Javier Loscertales, Tamara Mateu-Albero, Lorena Vega-Piris, Marina Espartero-Santos, Ana Marcos-Jimenez, Blanca Andrea Sánchez-López, et al.

    T-cell prolymphocytic leukemia (T-PLL) is a poor prognostic disease with very limited options of efficient therapies. Most patients are refractory to chemotherapies and despite high response rates after alemtuzumab, virtually all patients relapse. Therefore, there is an unmet medical need for novel therapies in T-PLL. As the chemokine receptor CCR7 is a molecule expressed in a wide range of malignancies and relevant in many tumor processes, the present study addressed the biologic role of this receptor in T-PLL. Furthermore, we elucidated the mechanisms of action mediated by an anti-CCR7 monoclonal antibody (mAb) and evaluated whether its anti-tumor activity would warrant development towards clinical applications in T-PLL. Our results demonstrate that CCR7 is a prognostic biomarker for overall survival in T-PLL patients and a functional receptor involved in the migration, invasion, and survival of leukemic cells. Targeting CCR7 with a mAb inhibited ligand-mediated signaling pathways and induced tumor cell killing in primary samples. In addition, directing antibodies against CCR7 was highly effective in T-cell leukemia xenograft models. Together, these findings make CCR7 an attractive molecule for novel mAb-based therapeutic applications in T-PLL, a disease where recent drug screen efforts and studies addressing new compounds have focused on chemotherapy or small molecules.